Search results
Results from the WOW.Com Content Network
Cyproheptadine has been reported to block 85% of 5-HT 2 receptors in the human brain at a dose of 4 mg three times per day (12 mg/day total) and to block 95% of 5-HT 2 receptors in the human brain at a dose of 6 mg three times per day (18 mg/day total) as measured with positron emission tomography (PET). [32]
2 times a day bis die sumendum b.i.d., bid, BID twice a day / twice daily bis in die gtt., gtts drop(s) gutta(e) h., h hour: hora: qhs, h.s., hs at bedtime or half strength quaque hora somni ii two tablets duos doses iii three tablets trēs doses n.p.o., npo, NPO nothing by mouth / not by oral administration: nil per os o.d., od, OD right eye
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
tablet 2, 4, 8, 16, 32 mg calcium stearate, cornstarch, lactose, mineral oil, sorbic acid, sucrose, and erythrosine sodium (2 mg only), FD&C yellow No. 6 (8 and 32 mg only) methylprednisolone Medrol Oral tablet 4 mg; 21 pills (dose-pack) calcium stearate, cornstarch, lactose, sucrose methylprednisolone acetate Depo-Medrol Parenteral:
o 2, o 2 both eyes "O 2" usually means oxygen or oxygen therapy: o.d. omni die: every day (once daily) (preferred to "qd" in the UK [10]) o.d. oculus dexter: right eye o can be mistaken as an a which could read "a.d.", meaning right ear, confusion with "omni die" o.m. omni mane: every morning omn. bih. omni bihora: every 2 hours omn. hor. omni ...
Side effects of thiocolchicoside can include nausea, allergy and vasovagal reactions. [15] Liver injury, pancreatitis, seizures, blood cell disorders, severe cutaneous disorders, rhabdomyolysis, and reproductive disorders have all been recorded in the French and European pharmacovigilance databases and in the periodic updates that the companies concerned submit to regulatory agencies.
Within 4–12 hours of the oral administration of a 10-mg dose to fasting adults, the attained mean ezetimibe peak plasma concentration (C max) was 3.4–5.5 ng/ml. Following oral administration, ezetimibe is absorbed and extensively conjugated to a phenolic glucuronide (active metabolite).
Following a 60-mg loading dose of the drug, about 90% of patients had at least 50% inhibition of platelet aggregation by one hour. Maximum platelet inhibition was about 80%. Mean steady-state inhibition of platelet aggregation was about 70% following three to five days of dosing at 10 mg daily after a 60-mg loading dose.